Novartis says REMODEL trials succeed, positioning remibrutinib for $4bn+ MS market
REMODEL-1 and REMODEL-2 hit their primary endpoint, and Novartis links remibrutinib to a USD 4bn+ relapsing multiple sclerosis opportunity, per TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
REMODEL-1 and REMODEL-2 both met their primary endpoint, showing lower relapse and MRI activity along with a favorable 6mCDP result, according to TradingView. The accompanying materials tie remibrutinib to a USD 4bn+ opportunity in relapsing multiple sclerosis (RMS).
The drug may also address further MS indications and other diseases, the summary states.
why it matters
For Novartis, the data strengthen the case for remibrutinib in a large neurology market. Investors will likely watch upcoming regulatory steps and results in other indications, since those will determine how much the drug adds to revenue. The news is company-specific, so its effect on broader markets should be limited.
market impact
Novartis (NOVN): positive trial data support the company's MS pipeline and sentiment in the neurology segment
tags
instruments
sources
- NOVN: REMODEL success positions remibrutinib for a USD 4bn+ RMS opportunity — TradingView, 23 October 2026 at 22:16 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗